Anondita Medi. (ANONDITA)

FairStock Score: 25/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Revenue growth of 72.24% and profit growth of 125.61% show strong momentum.
• Latest quarter net margin is healthy: ₹13 Cr net profit on ₹54 Cr sales (~24%).
• Promoter holding is high at 62.40%, aligning management with minority shareholders.
• Piotroski F-score of 6/9 suggests reasonably sound recent financials.
• PEG ratio of 0.60 indicates valuation may be reasonable if current growth persists.

Concerns

• P/E of 59.08 is rich, and the stock is near its 52-week high of ₹1,316, leaving little margin of safety.
• ROCE is reported as 0.00%, and no ROE, book value, or debt-equity data are available, making capital efficiency impossible to verify.
• Dividend yield is zero, so shareholders receive no income while waiting for growth.
• FairStock Score of 26/100 flags the stock as risky; even annualized latest-quarter profit of ~₹52 Cr implies a forward P/E of ~26x.

AI Analysis

At ₹1,200, Anondita Medi is being priced as a proven compounder, but the numbers don't yet prove that to me. Yes, 72.24% sales growth and 125.61% profit growth are impressive, and the latest quarter's 24% net margin (₹13 Cr profit on ₹54 Cr sales) shows momentum. A PEG of 0.60 is attractive only if that growth is durable. But Graham taught me to weigh the balance sheet and returns. Here I have no book value, no ROE, no debt-to-equity, and ROCE is stated as 0.00%. That is either a data problem or a real red flag. Without those, I cannot know whether this growth is being bought with leverage or genuinely high returns on capital. At 59 times trailing earnings, near the 52-week high of ₹1,316, the market is paying a full price. Zero dividend means no cash reward while I wait. Promoter holding at 62.40% is good for alignment, and the Piotroski F-score of 6/9 gives some comfort on recent financial health, but it is not a clean 9. FairStock Score of 26/100 reinforces my caution. Latest quarter annualizes to roughly ₹52 Cr profit, which makes the forward-looking multiple lower—about 26 times—but that assumes the fourth quarter is the new run-rate. For a personal-care company, brand loyalty and distribution matter; I cannot see a moat from these figures. I would watch this space, but not buy into a small-cap with unverified capital efficiency and a risky score. Better businesses at fair prices exist.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer